Normal metabolite levels in the left dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: A single voxel 1H spectroscopy study

Psychiatry Research - Neuroimaging

Volumn 174, Issue 3, 2009, Pages 177-183

  Nery, Fabiano G ^a,b,c   Stanley, Jeffrey A ^d   Chen, Hua Hsuan ^e   Hatch, John P ^a   Nicoletti, Mark A ^f   Monkul, Emel Serap ^a,b   Matsuo, Koji ^a,b   Caetano, Sheila C ^a,b,c   Peluso, Marco A ^a,b,c   Najt, Pablo ^a,b   Soares, Jair C ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Choline containing compounds; Glutamate; Magnetic resonance spectroscopy; Major depressive disorder; N acetyl aspartate; Pathophysiology; Phosphocreatine creatine; Prefrontal cortex

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PATHOPHYSIOLOGY; PATIENT SELECTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELIABILITY; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; ASPARTIC ACID; BRAIN MAPPING; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CREATINE; DEPRESSIVE DISORDER, MAJOR; FEMALE; FUNCTIONAL LATERALITY; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PHOSPHOCREATINE; PREFRONTAL CORTEX; PROTONS; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 72149094846     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2009.05.003     Document Type: Article

References (63)

1. Auer D.P., Putz B., Kraft E., Lipinski B., Schill J., and Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry 47 (2000) 305-313
2. Avery D.H., Holtzheimer III P.E., Fawaz W., Russo J., Neumaier J., Dunner D.L., Haynor D.R., Claypoole K.H., Wajdik C., and Roy-Byrne P. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biological Psychiatry 59 (2006) 187-194
3. Bartha R., Drost D.J., Menon R.S., and Williamson P.C. Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magnetic Resonance in Medicine 44 (2000) 185-192
4. Baslow M.H. Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. Journal of Neurochemistry 75 (2000) 453-459
5. Baxter Jr. L.R., Schwartz J.M., Phelps M.E., Mazziotta J.C., Guze B.H., Selin C.E., Gerner R.H., and Sumida R.M. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Archives of General Psychiatry 46 (1989) 243-250
6. Bessman S.P., and Geiger P.J. Transport of energy in the muscle: the phosphorylcreatine shuttle. Science 211 (1981) 448-452
7. Bhagwagar Z., Wylenzinska M., Taylor M., Jezzard P., Matthews P.M., and Cowen P.J. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. American Journal of Psychiatry 161 (2004) 368-370
8. Bhakoo K.K., and Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. Journal of Neurochemistry 74 (2000) 254-262
9. Biver F., Goldman S., Delvenne V., Luxen A., De Maertelaer V., Hubain P., Mendlewicz J., and Lotstra F. Frontal and parietal metabolic disturbances in unipolar depression. Biological Psychiatry 36 (1994) 381-388
10. 1H magnetic resonance spectroscopy study of dorsolateral prefrontal cortex in unipolar mood disorder patients. Psychiatry Research 138 (2005) 131-139
11. Caetano S.C., Fonseca M., Olvera R.L., Nicoletti M., Hatch J.P., Stanley J.A., Hunter K., Lafer B., Pliszka S.R., and Soares J.C. Proton spectroscopy study of the left dorsolateral prefrontal cortex in pediatric depressed patients. Neuroscience Letters 384 (2005) 321-326
12. Chakraborty G., Mekala P., Yahya D., Wu G., and Ledeen R.W. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. Journal of Neurochemistry 78 (2001) 736-745
13. Chang L., Ernst T., Poland R.F., and Jenden D.J. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sciences 58 (1996) 2049-2056
14. Cotter D., Mackay D., Chana G., Beasley C., Landau S., and Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cerebral Cortex 12 (2002) 386-394
15. Coupland N.J., Ogilvie C.J., Hegadoren K.M., Seres P., Hanstock C.C., and Allen P.S. Decreased prefrontal myo-inositol in major depressive disorder. Biological Psychiatry 57 (2005) 1526-1534
16. Dale A.M., Fischl B., and Sereno M. Cortical surface-based analysis, I: segmentation and surface reconstruction. NeuroImage 9 (1999) 179-194
17. de Graaf A.A., and Bovee W.M. Improved quantification of in vivo 1 H NMR spectra by optimization of signal acquisition and processing and by incorporation of prior knowledge into the spectral fitting. Magnetic Resonance in Medicine 15 (1990) 305-319
18. D'Esposito M. Executive functions and frontal systems. In: Schiffer R.B., Rao S.M., and Fogel B.S. (Eds). Neuropsychiatry. 2nd ed (2003), Lippincott Williams & Wilkins, Philadelphia, USA 328-337
19. Drevets W.C. Neuroimaging studies of mood disorders. Biological Psychiatry 48 (2000) 813-829
20. Eschweiler G.W., Wegerer C., Schlotter W., Spandl C., Stevens A., Bartels M., and Buchkremer G. Left prefrontal activation predicts therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychiatry Research 99 (2000) 161-172
21. Farchione T.R., Moore G.J., and Rosenberg D.R. Proton magnetic resonance spectroscopic imaging in pediatric major depression. Biological Psychiatry 52 (2002) 86-92
22. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis Disorders (1995), State Psychiatric Institute, Biometrics Research, New York, NY
23. Goff D.C., Hennen J., Lyoo K., Tsai G., Wald L.L., Evins A.E., Yurgelun-Todd D.A., and Renshaw P.F. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biological Psychiatry 15 (2002) 493-497
24. Hamilton M. Hamilton psychiatric rating scale for depression. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology (1976), U.S. Department of Health, Education and Welfare, Washington DCL 179-192
25. Hasler G., Neumeister A., van der Veen J.W., Tumonis T., Bain E.E., Shen J., Drevets W.C., and Charney D.S. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biological Psychiatry 58 (2005) 969-973
26. Hasler G., van der Veen W., Tumonis T., Meyers N., Shen J., and Drevets W.C. Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of General Psychiatry 64 (2007) 193-200
27. 1H-magnetic resonance spectroscopy of human brain: influence of composition and parameterization of the basis set in linear combination model-fitting. Magnetic Resonance in Medicine 48 (2002) 440-453
28. Jackson G.D., and Duncan J.S. MRI Anatomy: A New Angle on the Brain (1996), Churchill Livingstone, New York
29. Kato T., Takahashi S., Shioiri T., and Inubushi T. Brain phosphorus metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. Journal of Affective Disorders 26 (1992) 223-230
30. Kato T., Inubushi T., and Kato N. Magnetic resonance spectroscopy in affective disorders. Journal of Neuropsychiatry 10 (1998) 133-147
31. Kim H., McGrath B.M., and Silverstone P.H. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders - focus on magnetic resonance spectroscopy (MRS) studies. Human Psychopharmacology 20 (2005) 309-326
32. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., and Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 7 (2002) S71-S80
33. Kugaya A., and Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectrums 10 (2005) 808-819
34. Kumar A., Thomas A., Lavretsky H., Yue K., Huda A., Curran J., Venkatraman T., Estanol L., Mintz J., Mega M., and Toga A. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. American Journal of Psychiatry 159 (2002) 630-636
35. Magistretti P.J., and Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 354 (1999) 1155-1163
36. Mayberg H.S. Modulating dysfunctional limbic-cortical circuits in depression: towards the development of brain-based algorithms for diagnosis and optimized treatment. British Medical Bulletin 65 (2003) 193-207
37. Mayberg H.S., Liotti M., Brannan S.K., McGinnis S., Mahurin R.K., Jerabek P.A., Silva J.A., Tekell J.L., Martin C.C., Lancaster J.L., and Fox P.T. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. American Journal of Psychiatry 156 (1999) 675-682
38. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., and Pfleiderer B. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychological Medicine 33 (2003) 1277-1284
39. Murata T., Kimura H., Omori M., Kado H., Kosaka H., Iidaka T., Itoh H., and Wada Y. MRI white matter hyperintensities, (1)H-MR spectroscopy and cognitive function in geriatric depression: a comparison of early- and late-onset cases. International Journal of Geriatric Psychiatry 16 (2001) 1129-1135
40. Pfefferbaum A., Adalsteinsson E., Spielman E., Sullivan E.V., and Lim K.O. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magnetic Resonance in Medicine 41 (1999) 276-284
41. Pouwels P.J., Brockmann K., Kruse B., Wilken B., Wick M., Hanefeld F., and Frahm J. Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatric Research 46 (1999) 474-485
42. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 30 (1993) 672-679
43. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., Overholser J.C., Stockmeier C.A., and Ordway C.A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biological Psychiatry 45 (1999) 1085-1098
44. Ratiney H., Sdika M., Coenradie Y., Cavassila S., van Ormondt D., and Graveron-Demilly D. Time-domain semi-parametric estimation based on a metabolite basis set. NMR in Biomedicine 18 (2005) 1-13
45. Robinson R.G., and Szetela B. Mood change following left hemispheric brain injury. Annals of Neurology 9 (1981) 447-453
46. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., and Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. Journal of the American Academy of Child and Adolescent Psychiatry 39 (2000) 1096-1103
47. Rothman D.L., Sibson N.R., Hyder F., Shen J., Behar K.L., and Shulman R.G. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 354 (1999) 1165-1177
48. Sanacora G., Mason G.F., Rothman D.L., and Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. American Journal of Psychiatry 159 (2002) 663-665
49. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Krystal J.H., and Mason G.F. Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 61 (2004) 705-713
50. Seeger U., Klose U., Mader I., Grodd W., and Nagele T. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magnetic Resonance in Medicine 49 (2003) 19-28
51. Sheline Y.I. Neuroimaging studies of mood disorder effects on the brain. Biological Psychiatry 54 (2003) 338-352
52. Shen J., and Rothman D.L. Magnetic resonance spectroscopic approaches to studying neuronal: glial interactions. Biological Psychiatry 52 (2002) 694-700
53. Silverstone P.H., Wu R.H., O'Donnell T., Ulrich M., Asghar S.J., and Hanstock C.C. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Human Psychopharmacology 17 (2002) 321-327
54. Silverstone P.H., Wu R.H., O'Donnell T., Ulrich M., Asghar S.J., and Hanstock C.C. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. International Clinical Psychopharmacology 18 (2003) 73-79
55. Smith S.M., Jenkinson M., Woolrich M., Beckmann C.F., Behrens T.E., Johansen-Berg H., Bannister P.R., De Luca M., Drobnjak I., Flitney D.E., Niazy R.K., Saunders J., Vickers J., Zhang Y., De Stefano N., Brady J.M., and Matthews P.M. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 23 suppl 1 (2004) S208-S219
56. Soares J.C., and Mann J.J. The anatomy of mood disorders - review of structural neuroimaging studies. Biological Psychiatry 41 (1997) 86-106
57. Stanley J.A. In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. Canadian Journal of Psychiatry 47 (2002) 315-326
58. 1H MR spectra. Magnetic Resonance in Medicine 34 (1995) 17-24
59. Stanley J.A., Pettegrew J.W., and Keshavan M.S. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings - part I. Biological Psychiatry 48 (2000) 357-368
60. Stork C., and Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Molecular Psychiatry 10 (2005) 900-919
61. Urenjak J., Williams S.R., Gadian D.G., and Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. Journal of Neuroscience 13 (1993) 981-989
62. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. European Archives of Psychiatry and Clinical Neurosciences 248 (1998) 289-295
63. Zarate Jr. C.A., Du J., Quiroz J., Gray N.A., Denicoff K.D., Singh J., Charney D.S., and Manji H.K. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders. Role of the glutamatergic system. Annals of the New York Academy of Sciences 1003 (2003) 273-291